If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ONCOLOGY<br /> EMJ Oncol. 2019 Suppl 1 • europeanmedical-journal.com<br /> INSIDE<br /> A Review of Gene Expression<br /> Profiling in Early-Stage<br /> ER+/HER2- Breast Cancer<br /> With A Focus on The PAM50<br /> Risk of Recurrence Assay<br /> A Review of Gene Expression Profiling in<br /> Early-Stage ER+/HER2- Breast Cancer With A<br /> Focus on The PAM50 Risk of Recurrence Assay<br /> Authors: *Malek B. Hannouf,1 Christine Brezden-Masley,2,3 Jacques Raphael,4<br /> Muriel Brackstone1,4<br /> 1. Department of Surgery, Schulich School of Medicine and Dentistry, Western<br /> University, London, Canada<br /> 2. Faculty of Medicine, University of Toronto, Toronto, Canada<br /> 3. Division of Hematology and Oncology, St. Michael’s Hospital, Toronto, Canada<br /> 4. Department of Oncology, Schulich School of Medicine and Dentistry, Western<br /> University, London Regional<a title="EMJ Oncol. 2019 Suppl 1 page 1" href="http://viewer.zmags.com/publication/f53cdf2e?page=1"> ONCOLOGY EMJ Oncol. 2019 Suppl 1 • europeanmedica</a> <a title="EMJ Oncol. 2019 Suppl 1 page 2" href="http://viewer.zmags.com/publication/f53cdf2e?page=2"> A Review of Gene Expression Profiling in Ear</a> <a title="EMJ Oncol. 2019 Suppl 1 page 3" href="http://viewer.zmags.com/publication/f53cdf2e?page=3"> INTRODUCTION Over 70% of patients with early-stag</a> <a title="EMJ Oncol. 2019 Suppl 1 page 4" href="http://viewer.zmags.com/publication/f53cdf2e?page=4"> Table 1: First and second-generation multigene pr</a> <a title="EMJ Oncol. 2019 Suppl 1 page 5" href="http://viewer.zmags.com/publication/f53cdf2e?page=5"> Table 1 continued. Name (manufacturer) Inform</a> <a title="EMJ Oncol. 2019 Suppl 1 page 6" href="http://viewer.zmags.com/publication/f53cdf2e?page=6"> The prognostic significance of Prosigna was c</a> <a title="EMJ Oncol. 2019 Suppl 1 page 7" href="http://viewer.zmags.com/publication/f53cdf2e?page=7"> widely used tool in the NHS and Adjuvant! Online </a> <a title="EMJ Oncol. 2019 Suppl 1 page 8" href="http://viewer.zmags.com/publication/f53cdf2e?page=8"> incremental cost-effectiveness ratios (ICER) of £</a> <a title="EMJ Oncol. 2019 Suppl 1 page 9" href="http://viewer.zmags.com/publication/f53cdf2e?page=9"> Table 3: Guidelines supporting the use of Prosign</a> <a title="EMJ Oncol. 2019 Suppl 1 page 10" href="http://viewer.zmags.com/publication/f53cdf2e?page=10"> fully assess the cost-effectiveness of the tests </a> <a title="EMJ Oncol. 2019 Suppl 1 page 11" href="http://viewer.zmags.com/publication/f53cdf2e?page=11"> than in patients receiving chemotherapy. It was t</a> <a title="EMJ Oncol. 2019 Suppl 1 page 12" href="http://viewer.zmags.com/publication/f53cdf2e?page=12"> endocrine treatment: A combined analysis of patie</a> <a title="EMJ Oncol. 2019 Suppl 1 page 13" href="http://viewer.zmags.com/publication/f53cdf2e?page=13"> cancer 2015. Clin Transl Oncol. 52</a>